Treatment of advanced epithelial ovarian cancer with a cis-dichloro-diammine platinum, cyclophosphamide, and bleomycin combination

Twenty-five consecutive patients with previously untreated stage III (18) and IV (7) epithelial ovarian carcinoma underwent maximum surgical tumor reduction followed by cyclophosphamide, cisplatinum, and bleomycin chemotherapy, given 5 days every 3 weeks for a total of 6-8 courses. Patients were the...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of clinical oncology Vol. 11; no. 1; p. 7
Main Authors Israël, L, Breau, J L, Morère, J F, Aguilera, J
Format Journal Article
LanguageEnglish
Published United States 01.02.1988
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bleomycin - administration & dosage
Carcinoma - drug therapy
Carcinoma - surgery
Cisplatin - administration & dosage
Cyclophosphamide - administration & dosage
Female
Humans
Middle Aged
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - surgery
Prognosis
Reoperation
Online AccessGet more information

Cover

More Information
Summary:Twenty-five consecutive patients with previously untreated stage III (18) and IV (7) epithelial ovarian carcinoma underwent maximum surgical tumor reduction followed by cyclophosphamide, cisplatinum, and bleomycin chemotherapy, given 5 days every 3 weeks for a total of 6-8 courses. Patients were then submitted to second-look surgery, and complete responders to a 1-year additional chemotherapy with L phenylalanine mustard and hexamethylmelamine. The median survival is 23 months for the whole group, and 31+ months for 13 patients found in microscopically assessed complete remission (CR) at the time of second-look surgery. The possible significance of these results and of the addition of bleomycin to a well-known combination are discussed, together with the limitations of a phase II study.
ISSN:0277-3732
DOI:10.1097/00000421-198802000-00003